Detection - Data from Matritech's NMP66 Breast Cancer Blood Test Presented at 2

June 21, 2005

http://www.nfcr.org/html/research_discov/news_sep_15f.html

Data from Matritech's NMP66 Breast Cancer Blood Test Presented at 28th Meeting Of The ISOBM, One of The World's Preeminent Cancer Organizations

NEWTON, Mass., Sept. 11 /PRNewswire/ -- Matritech, Inc. (Nasdaq: NMPS), a company developing products to detect and manage cancer, announced today that data reported in its June 1st news release relevant to the company's NMP66 blood test for the detection of breast cancer has been formally presented at the 28th Meeting of the International Society for Oncodevelopmental Biology and Medicine (ISOBM) in Munich, Germany. The presentation was made by Dr. Brynmor Watkins, Ph.D., Matritech's Director of Research and the scientist who discovered NMP66. Blood specimens from seventy-eight women have been tested using Matritech's proprietary specimen preparation and mass spectrometry procedures. Forty-five of these specimens came from women diagnosed with breast cancer in various stages of the disease and 5 were from women with Ductal Carcinoma In Situ (DCIS), a condition that can progress to cancer. An additional 28 specimens came from women who had no breast disease or had been diagnosed as having benign breast disease. NMP66 was found in the blood of every woman who was diagnosed with cancer and was absent in all of the 'normal' specimens. "We are pleased that one of the most prestigious international cancer organizations selected NMP66 as an emerging cancer test to be presented to its membership of scientists and physicians," said Stephen D. Chubb, chairman and chief executive officer of Matritech. "The ISOBM board reviewed the NMP66 material prior to acceptance for presentation by Dr. Watkins. We believe the discussion of these results at this forum will aid us in achieving prompt clinical introduction of the NMP66 test. "When breast cancer is discovered at its earliest stage, the five-year survival rate is well over 90 percent," added Chubb. "Further testing and development of this breast cancer blood test is therefore of the highest priority for Matritech going forward." Matritech's nuclear matrix protein (NMP) core technology correlates levels of NMPs in body fluids to the presence of cancer. Multiple published clinical studies have validated this ability of NMPs to detect early-stage cancerous abnormalities. Matritech has a deep pipeline of NMP-based products in preclinical and clinical development for the detection of major cancers including bladder, cervical, breast, prostate and colon cancers. The NMP22 Test Kit is cleared for marketing in the United States for management and screening of individuals at risk of bladder cancer. It is also sold in Europe and Japan, where it is approved for bladder cancer screening. Matritech Inc., based in Newton, Mass., is using its proprietary nuclear matrix protein (NMP) technology, discovered at the Massachusetts Institute of Technology, and licensed exclusively to Matritech, to develop and commercialize innovative serum-, cell- and urine-based NMP diagnostics that enable physicians to reliably detect and monitor the presence of the major human cancers. Statement Under the Private Securities Litigation Reform Act Any forward looking statements related to the Company's expectations regarding the performance, timing or extent of market acceptance, and regulatory approvals of the Company's breast cancer test are subject to a number of risks and uncertainties, many of which are beyond the Company's control. These include, but are not limited to, risks related to the Company's limited capital resources, unforeseen delays in product development, results of fullscale clinical trials, unforeseen delays or denials of FDA and other regulatory approvals, future product demand and pricing, competitive products and technical developments and general business and economic conditions. There can be no assurances that the Company's expectations for its products will be achieved. Stephen D. Chubb, CEO David L. Corbet, President Matritech, Inc. 617-928-0820 Derek Caldwell Investor Relations Sunrise Financial Group 212-421-1616 Jon Siegal Media Relations Ronald Trahan Associates, Inc. 508-647-9782, ext. 15 SOURCE Matritech, Inc.